^
    Back
    Association details:
    Biomarker:FGFR2-BICC1 fusion
    Cancer:Biliary Tract Cancer
    Drug Class:FGFR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Hepatol
    Title:

    Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

    Published date:
    11/09/2023
    Excerpt:
    Introduction of FGFR2-BICC1 into biliary tract cells in vitro sensitized the cells to FGFRi, while concomitant KRAS G12D or BRAF V600E conferred resistance.
    DOI:
    https://doi.org/10.1016/j.jhep.2023.10.041